Your browser doesn't support javascript.
loading
Gastrointestinal and genitourinary symptoms in facioscapulohumeral muscular dystrophy: Prevalence and impact.
Cole, Michael R; Cooper, Christopher S; Hanna, Eyad M; Zimmerman, M Bridget; Kinoshita, June; Mathews, Katherine D.
Afiliação
  • Cole MR; Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
  • Cooper CS; Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
  • Hanna EM; Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
  • Zimmerman MB; Department of Biostatistics, University of Iowa College of Public Health, Iowa City, Iowa, USA.
  • Kinoshita J; FSHD Society, Randolph, Massachusetts, USA.
  • Mathews KD; Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Muscle Nerve ; 69(3): 325-333, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38158588
ABSTRACT
INTRODUCTION/

AIMS:

Anecdotally, patients with facioscapulohumeral muscular dystrophy (FSHD) describe gastrointestinal (GI) and genitourinary (GU) symptoms. We explored the prevalence of GI and GU symptoms and their impact on quality of life (QOL) in people with FSHD compared to healthy household controls.

METHODS:

In this descriptive, cross-sectional study, we emailed a survey exploring GI and GU symptoms to all FSHD Society patient contacts (n = 3507). We invited those with FSHD and unaffected household controls to respond. Non-parametric statistics were used to compare symptom frequency and impact of symptoms between respondents with FSHD and household controls. Within the FSHD group, symptom frequency was assessed relative to measures of disease progression (need for ambulatory or respiratory support).

RESULTS:

Surveys from 701 respondents (652 with FSHD) ≥18 years old were included in analysis. Those with FSHD had symptoms affecting both GI and GU systems more frequently than controls using ordinal rating of symptom frequency. Within the FSHD group, more advanced disease was associated with increased symptom frequency. QOL was negatively impacted by the GI and GU symptoms. There was no difference between groups in use of medications to treat these symptoms.

DISCUSSION:

Recognition and treatment of GI and GU symptoms in people with FSHD, particularly those with more advanced disease, could improve QOL. Additional investigation is required to confirm these findings and understand the physiology.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular Facioescapuloumeral Limite: Adolescent / Humans Idioma: En Revista: Muscle Nerve Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular Facioescapuloumeral Limite: Adolescent / Humans Idioma: En Revista: Muscle Nerve Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos